Provexis Share Discussion Threads

[winner31] 06/1/2020 11:16

This is a bit out of date but relevant . . The Number of Approved Health Food Registration Products with Different Health Functions

Among the 153 approved health food registration products, 33 products lack health function information.

Among the 120 approved health food registration products (the health functions of these products have been announced), 112 products have one health function. The health function of these products is mainly enhancing immune, with the number of 80, accounting for 71.43% of the 112 products. 8 products have two health functions, the health functions of these products are mainly enhancing immune and alleviating physical fatigue, with the number of 3, accounting for 37.50% of the 8 products.

Among the 33 approved health food registration products (the health functions of these products have not been announced), it is speculated from the raw materials of the products that the health function is mainly enhancing immune. But the specific quantity of related products should be confirmed after the health functions are officially announced.

[gix er] 04/1/2020 07:52

Exactly BB,

We are all just guessing atm.

Edit.

Just to make a point.

We were told that BY-HEALTH were "intending to make its first submission to the SAMR for Fruitflow® in February 2019."

But still don't know if this happened.
Blue Cap (Hat) is not a quick process so lets hope they got the ball rolling.

[bareknee] 03/1/2020 22:26

Gixer

Yea, that's right, but I've always interpreted those words ( which aren't new ) as the trials being done are ( all ??? ) being used to support the blue cap process, while some of them are also for the "other regulatory submissions", so I'm not sure it makes much difference in the grand scheme of things ?

If we had any idea about how many seperate blue cap submissions we were making, and what exactly they were, then we could make educated guesses as to which trials were for which submission, but, as you've pointed out before, we're pretty much in the dark.

My gut reaction is there'll be one main blue cap submission, possibly with later amendments for slightly different uses, but, but to honest, I'm totally clueless.

BB

[gix er] 03/1/2020 08:48

According to the update in the interim results the studies are not just for Blue Hat.

"The five completed studies showed excellent results in use for Fruitflow, and they provide strong evidence for By-Health in its blue cap and other regulatory submissions to the SAMR for Fruitflow, supported by the Company’s existing European Food Safety Authority (‘EFSA’) health claim for Fruitflow."

[bareknee] 02/1/2020 19:54

I've no idea how rigorous the Chinese system is compared to EFSA ( though, I'd guess it's less rigorous ? ) , but, from the EFSA documentation at


"The substantiation of the claimed effect is based on eight human studies (seven claimed as proprietary and conducted with WSTC) and seven (three claimed as proprietary) non human studies."

So 15 in all, though only 10 of those are proprietary.

Incidentally, that paperwork's from just over ten years ago, which makes me realise just how little we all knew ( well, me anyway ) about the commercialisation process and timescales.

BB

[redprince] 02/1/2020 18:28

Winner..I think fixer may be on the right track (se above) because 7 trials must surely cover a number of uses of FF and presumably a number of potential applications.
We now have 5 of them in the bag.
The question is how many per Blue Hat application and how many Blue Hat before a launch?
We only need one launch to get the share price going in the right direction because it should hopefully become a rolling stone of momentum after that!

[gix er] 02/1/2020 18:13

could also be different studies for different health claims.
blood pressure?
circulation?
exercise?
air pollution?
something else????

A By-Health patent has already been published for a blood pressure lowering product containing Fruitflow.

[winner31] 02/1/2020 17:22

Rp of course it’s possible but the 2 first completed study’s was about a year ago and nothing has come of that yet !

[redprince] 02/1/2020 17:00

It is possible that they could launch something before all tests are complete though?
We do not know what all the tests are for and how many are for Blue Hat accreditation.

[winner31] 02/1/2020 08:02

The trouble is if they commission more studies say 12 will we have to wait for all studies to complete,like you say we could have a long wait ahead unfortunately

[twodegrees] 01/1/2020 22:01

Winner I agree, they will probably have to wait on all results for full clarification. In any case I would suggest that the next 12 months will be loss making as revenues even if they rise at the same pace as they have done in the past 12 months will still leave them in a loss making situation . They will come back for more funds meaning more dillution. I would say we are in an 18 month to 24 month transition before we might see a profit. I would suggest then and am giving myself this advise now, to buy on the dips and average down.

[winner31] 01/1/2020 09:28

Looks like they will wait for all 9 studies before getting Samr approval , disappointing

[twodegrees] 31/12/2019 15:10

Bareknee. I totally agree, they will need more cash.

[twodegrees] 31/12/2019 10:32

redprince, greetings, I suppose it depends if you think within the next 12 months it will no longer be making a loss. A few years down the line I think profits will emerge but in the meantime we have to wait for China because I see that as being the only way forward that revenues will increase. But what do I know....

[redprince] 31/12/2019 10:04

twodegrees - it does not state that it will have to - it states that while it remains loss making it will.

Where does it say that it is expected to reman loss maing?

That is my reading of it anyway.

Not saying they won't have to just that it is unclear from the rns and given the modest amout raised...

[twodegrees] 31/12/2019 09:06

Capital structure and funding

On 11 December 2019 the Group announced it had raised proceeds of GBP301,333 via the placing of 75,333,333 new ordinary shares of 0.1p each at a gross 0.40p per share with investors, with no commissions payable. The placing shares were admitted to trading on AIM on 17 December 2019.

The Company is seeking to maximise the commercial returns that can be achieved from its Fruitflow technology, and the Company's cost base and its resources continue to be very tightly managed. The Company remains keen to minimise dilution to shareholders and it is focussed on moving into profitability as Fruitflow revenues increase, but while the Company remains in a loss-making position it will need to raise funds to support working capital on occasions.

[twodegrees] 31/12/2019 09:05

redprince, read the rns, it does state they may need to raise more funds

[bennywin] 31/12/2019 09:02

A corner shops does those kind of sales in a week.

[redprince] 31/12/2019 08:50

twodegrees - does it though?You cannot be certain of that as there is insufficient information to tell you either way.

Personally i am taking the relatively modest fund raising as a positive sign.

Dyor.Aimho.

[twodegrees] 31/12/2019 08:39

funding will still be needed, so why did they not raise more at the last raise, means they will be coming back again....

[twodegrees] 31/12/2019 08:29

losses reduced, sales up, small progress